Stock Analysts’ Updated EPS Estimates for January, 13th (NTEC, NTR, NTTYY, NVCR, NWPHF, NYLD, OAKS, OCX, OLBK, PDRDY)

Stock Analysts’ updated eps estimates for Saturday, January 13th:

Intec Pharma (NASDAQ:NTEC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $8.00 target price on the stock. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

Nutrien (NYSE:NTR) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $61.00 target price on the stock. According to Zacks, “Nutrien Ltd. produces and sells fertilizers and related industrial and feed products. The company’s products primarily include standard and granular potash; diammonium phosphate, monoammonium phosphate and phosphoric acid and ammonia, urea, nitric acid, ammonium nitrate and nitrogen solutions, as well as purified acids and phosphate feed products. Nutrien Ltd., formerly known as Potash Corporation of Saskatchewan Inc., is headquartered in Saskatoon, Canada. “

Nippon Telegraph and Telephone (OTCMKTS:NTTYY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Nippon Telegraph & Telephone provides a variety of telecommunications services, including telephone, telegraph, leased circuits, data communication, terminal equipment sales and other services. The Company provides both local and long distance telephone services within Japan, but it does not provide service in the international markets. “

Novocure (NASDAQ:NVCR) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “

Newron Pharma (OTCMKTS:NWPHF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Newron Pharmaceuticals SpA is a biopharmaceutical company. It focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain primarily in Italy and internationally. Newron Pharmaceuticals SpA is headquartered in Bresso, Italy. “

NRG Yield, Inc. Class C (NYSE:NYLD) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “NRG Yield, Inc. acquires, owns and operates contracted renewable and conventional generation as well as thermal infrastructure assets primarily in the United States through its subsidiaries. NRG Yield, Inc. is based in Princeton, New Jersey. “

Five Oaks Investment (NYSE:OAKS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Five Oaks Investment Corp. is a real estate investment trust. The company is focused on investing, financing and managing both agency and non-agency residential mortgage-backed securities, residential mortgage loans and other mortgage related investments. Five Oaks Investment Corp. is based in New York, United States. “

OncoCyte (NYSEAMERICAN:OCX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $4.75 price target on the stock. According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

Old Line Bancshares, Inc. (MD) (NASDAQ:OLBK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $34.00 target price on the stock. According to Zacks, “Old Line Bancshares is the parent company of Old Line Bank, a Maryland chartered commercial bank headquartered in Waldorf, Maryland. Old Line Bank’s primary market area is the suburban Maryland (Washington, D.C. suburbs) counties of Prince George’s, Charles and northern St. Mary’s. It also targets customers throughout the greater Washington, D.C. metropolitan area. “

Pernod Ricard (OTCMKTS:PDRDY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $36.00 target price on the stock. According to Zacks, “Pernod Ricard SA, based in France, operates as a manufacturer and seller of a wide range of wines and spirits. The company operates as holding company, with the structure divided between brand owner subsidiaries, such as The Absolut Company, Havana Club International and Chivas Brothers, which produce and develop marketing strategies for the brands, and regional distribution subsidiaries, such as Pernod Ricard Europe, Pernod Ricard Americas and Pernod Ricard Asia, which implement marketing strategies and distribute local brands. The Company is active in eight principal beverage sectors: whiskies, aniseed spirits, liqueurs, cognacs and brandies, white spirits and rums, bitters, champagnes and wines. Pernod Ricard SA’s flagship brands include Ricard, Havana Club, Ballantine’s, Malibu, Martell, The Glenlivet, Chivas Regal, Jameson and Absolut Vodka, among others. “

Preferred Bank (NASDAQ:PFBC) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $73.00 target price on the stock. According to Zacks, “Preferred Bank is one of the largest independent commercial banks in California focusing on the Chinese-American market. The bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Company conducts its banking business from its main office in Los Angeles, California, and through ten full-service branch banking offices in Alhambra, Century City, Chino Hills, City of Industry, Torrance, Arcadia, Irvine, Diamond Bar, Santa Monica and Valencia, California. Preferred Bank offers a broad range of deposit and loan products and services to both commercial and consumer customers. The bank provides personalized deposit services as well as real estate finance, commercial loans and trade finance to small and mid- sized businesses, entrepreneurs, real estate developers, professionals and high net worth individuals. Preferred Bank continues to benefit from the significant migration to Southern California of “

PLDT (NYSE:PHI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “PLDT Inc. offers telecommunications services. Its operating segment consists of Wireless, Fixed Line and Others. Wireless segment provides cellular, wireless broadband and other services, and digital platforms and mobile financial services. Fixed Line segment provides local exchange, international long distance, national long distance, data and other network and miscellaneous services. It offers postpaid and prepaid fixed line services. PLDT, Inc., formerly known as Philippine Long Distance Telephone Company, is based in Makati City, the Philippines. “

Proto Labs (NYSE:PRLB) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $120.00 target price on the stock. According to Zacks, “Proto Labs, Inc. is an online and technology-enabled quick-turn manufacturer of custom parts for prototyping and short-run production. It produces CNC machined and injection molded plastic parts. Proto Labs targets their services to product developers who use three-dimensional computer-aided design to develop products across a diverse range of end-markets. The Company has locations in the United States, the United Kingdom, Germany, Japan, Italy, France, and Spain. Proto Labs, Inc. is headquartered in Maple Plain, Minnesota. “

Premier Foods (OTCMKTS:PRRFY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.00 price target on the stock. According to Zacks, “Premier Foods plc, along with its subsidiaries, is engaged in the manufacturing, processing, and distribution of food and beverage products in the United Kingdom and other European countries. The Company operates in three divisions: Grocery, Hovis and Chilled. Grocery division is comprised of cakes, soups, vegetables, stocks, gravies, spreads, desserts. Hovis segment is comprised of wrapped bread, morning goods, and frozen part-baked products. The chilled segment is comprised of chilled and frozen meat-free products and chilled ready meal. The top brands offered by the company include: Hovis, Mr. Kipling, Quorn, Sharwoods, Cadbury, Bisto, Branston, Ambrosia, Loyd Grossman and Batchelors. Premier Foods plc is headquartered in St Albans, the United Kingdom. “

Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit